Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xilonix in Symptomatic Refractory Colorectal Cancer
NCT02138422Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) and cachexia comparing Xilonix with Placebo (2 arms). Primary endpoint: Clinical Response Rate at 8 weeks. Started Jul 2014; status: completed.
02
Drugs
bermekimab
03
Conditions
colorectal cancer (CRC)cachexia
Beyond the preview
Go deeper on NCT02138422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138422.